

Supplementary Table 3. Subgroup Analysis of Change from Baseline in DAS28-ESR at Week 24

	Adalimumab 40 mg q2w (n=185)	Sarilumab 200 mg q2w (n=184)
MTX history		
Inadequate responders, n	92	89
Mean (SD)	4.4 (1.4)	3.6 (1.5)
LS mean change from baseline (SE)	-2.3 (0.2)	-3.2 (0.2)
Mean difference, 95% CI vs adalimumab	—	-0.891 (-1.293, -0.489)
Intolerant/Inappropriate to continue, n*		
Mean (SD)	4.7 (1.3)	3.2 (1.4)
LS mean change from baseline (SE)	-2.1 (0.2)	-3.4 (0.2)
Mean difference, 95% CI vs adalimumab	—	-1.253 (-1.660, -0.846)
Treatment-by-subgroup interaction	—	<i>P</i> =0.2163
Baseline corticosteroid use		
Yes, n	92	83
Mean (SD)	4.3 (1.1)	3.7 (1.5)
LS mean change from baseline (SE)	-2.3 (0.1)	-3.1 (0.1)
Mean difference, 95% CI vs adalimumab	—	-0.806 (-1.168, -0.444)
No, n	71	82
Mean (SD)	4.7 (1.6)	3.3 (1.4)
LS mean change from baseline (SE)	-2.0 (0.2)	-3.4 (0.2)
Mean difference, 95% CI vs adalimumab	—	-1.402 (-1.856, -0.948)
Treatment-by-subgroup interaction	—	<i>P</i> =0.0414
RA duration		
≤3 years, n	73	53
Mean (SD)	4.5 (1.5)	3.4 (1.5)
LS mean change from baseline (SE)	-2.3 (0.2)	-3.3 (0.2)
Mean difference, 95% CI vs adalimumab	—	-1.087 (-1.580, -0.594)
>3 years, n	90	112
Mean (SD)	4.5 (1.3)	3.5 (1.4)

LS mean change from baseline (SE)	-2.3 (0.1)	-3.3 (0.1)
Mean difference, 95% CI vs adalimumab	—	-1.037 (-1.392, -0.681)
Treatment-by-subgroup interaction	—	<i>P</i> =0.8465
Region†		
Region 1, n	52	52
Mean (SD)	4.3 (1.4)	3.1 (1.3)
LS mean change from baseline (SE)	-2.3 (0.2)	-3.5 (0.2)
Mean difference, 95% CI vs adalimumab	—	-1.172 (-1.689, -0.656)
Region 2, n	32	32
Mean (SD)	4.7 (1.1)	3.9 (1.4)
LS mean change from baseline (SE)	-2.3 (0.2)	-3.1 (0.2)
Mean difference, 95% CI vs adalimumab	—	-0.809 (-1.394, -0.224)
Region 3, n	79	81
Mean (SD)	4.6 (1.4)	3.6 (1.5)
LS mean change from baseline (SE)	-2.1 (0.2)	-3.3 (0.2)
Mean difference, 95% CI vs adalimumab	—	-1.154 (-1.576, -0.731)
Treatment-by-subgroup interaction	—	<i>P</i> =0.6213

*One patient was deemed inappropriate to continue MTX treatment.

†Region 1: Czech Republic, Germany, Hungary, Israel, Spain, and United States. Region 2: Chile and Peru. Region 3: South Korea, Poland, South Africa, Romania, Russia, and Ukraine.

CI, confidence interval; DAS28-ESR, 28-joint disease activity score using erythrocyte sedimentation rate; LS, least squares; MTX, methotrexate; q2w, every 2 weeks; RA, rheumatoid arthritis; SD, standard deviation; SE, standard error.